



REPUBLIC OF THE PHILIPPINES
OFFICE OF THE PRESIDENT

DANGEROUS DRUGS BOARD

**BOARD REGULATION NO. 1
Series of 2022**

SUBJECT: EXTENDING THE GRANT OF THE PROVISIONAL REMOVAL OF LIANHUA QINGWEN FROM THE LIST OF DANGEROUS DRUGS FOR ANOTHER PERIOD OF ONE (1) YEAR

WHEREAS, the Dangerous Drugs Board (the “Board”) under Section 81 of Republic Act No. 9165 (RA 9165) or the Comprehensive Dangerous Drugs Act of 2002 is mandated to “formulate guidelines, in coordination with other government agencies, relative to transactions involving dangerous drugs and controlled precursors and essential chemicals, which may include the importation, distribution, sale, prescription, and dispensing thereof”;

WHEREAS, pursuant to the above mandate, the Board allowed the registration of Lianhua Qingwen capsules with the Food and Drug Administration of the Department of Health, through Board Resolution No. 1, Series of 2020 that was further supported by Board Resolution No. 8, Series of 2020 providing for the “Reiteration of Regulatory Requirements for Lianhua Qingwen Capsules”;

WHEREAS, on 4 February 2021, the Board promulgated Regulation No. 1, Series of 2021 approving the Provisional Removal of Lianhua Qingwen from the List of Dangerous Drugs for a Period of One Year pursuant to Section 93 of RA 9165 which further provides that prior to the expiration of the one-year period, the Committee on Reclassification shall evaluate and recommend to the Board whether to shorten or extend the said period given the prevailing circumstances at such time;

WHEREAS, the Philippine Archipelago International Trading Corporation in its letter dated 5 January 2022 addressed to the Board requesting for One Year Extension of Removal of Lianhua Qingwen Capsule from the List of Dangerous Drugs due to the surge of COVID-19 cases, specifically the rise of the Omicron variant;

WHEREAS, since the introduction of Lianhua Qingwen capsules in the Philippine market, there had been no reports of adverse drug reactions, nor any reports of abuse despite the product having trace/negligible amounts of ephedra, a known dangerous drug under Philippine laws, as an active component. Lianhua Qingwen has so far been an alternative affordable option for most Filipinos with mild COVID-19 symptoms;

WHEREFORE, be it **RESOLVED**, as it is hereby **RESOLVED**, to approve the extension of the provisional removal of Lianhua Qingwen from the list of dangerous drugs for another period of one year.

APPROVED and **ADOPTED** this 24th day of January in the year of Our Lord, 2022 in Quezon City.


Secretary CATALINO S. CUY, CEO VI
Chairman

Attested by:


Undersecretary EARL P. SAAVEDRA, CESE
Secretary of the Board